HK1201772A1 - Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate - Google Patents

Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate Download PDF

Info

Publication number
HK1201772A1
HK1201772A1 HK15102403.0A HK15102403A HK1201772A1 HK 1201772 A1 HK1201772 A1 HK 1201772A1 HK 15102403 A HK15102403 A HK 15102403A HK 1201772 A1 HK1201772 A1 HK 1201772A1
Authority
HK
Hong Kong
Prior art keywords
egfr
resistant
tumors
treatment
cytotoxic agent
Prior art date
Application number
HK15102403.0A
Other languages
English (en)
Chinese (zh)
Inventor
Julianto Setiady
Peter U. Park
Thomas Chittenden
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of HK1201772A1 publication Critical patent/HK1201772A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15102403.0A 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate HK1201772A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161562157P 2011-11-21 2011-11-21
US61/562,157 2011-11-21
US201261639452P 2012-04-27 2012-04-27
US61/639,452 2012-04-27
PCT/US2012/066205 WO2013078271A1 (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Publications (1)

Publication Number Publication Date
HK1201772A1 true HK1201772A1 (en) 2015-09-11

Family

ID=48470279

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102403.0A HK1201772A1 (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Country Status (16)

Country Link
US (1) US9233171B2 (cg-RX-API-DMAC7.html)
EP (1) EP2794010A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014533954A (cg-RX-API-DMAC7.html)
KR (1) KR20140105765A (cg-RX-API-DMAC7.html)
CN (1) CN104066481A (cg-RX-API-DMAC7.html)
AU (1) AU2012340686A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014012155A2 (cg-RX-API-DMAC7.html)
CA (1) CA2856411A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014001282A1 (cg-RX-API-DMAC7.html)
HK (1) HK1201772A1 (cg-RX-API-DMAC7.html)
IL (1) IL232666A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014006087A (cg-RX-API-DMAC7.html)
PH (1) PH12014501119A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014121820A (cg-RX-API-DMAC7.html)
SG (1) SG11201402343SA (cg-RX-API-DMAC7.html)
WO (1) WO2013078271A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
PT2668209T (pt) 2011-01-24 2021-04-07 Gilead Sciences Inc Anticorpos seletivos para células que apresentam egfr em alta densidade
EP2794010A4 (en) 2011-11-21 2015-10-21 Immunogen Inc METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
AU2014286872B2 (en) * 2013-07-05 2020-01-23 Formation Biologics Inc. EGFR antibody conjugates
WO2015035410A1 (en) * 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
CN113425727A (zh) 2014-02-04 2021-09-24 安斯泰来制药株式会社 以二氨基杂环甲酰胺化合物为有效成分的医药组合物
CN110841074B (zh) * 2014-03-21 2023-07-18 艾伯维公司 抗-egfr抗体及抗体药物偶联物
CN109147874A (zh) 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
MA40968A (fr) * 2014-10-31 2017-10-04 Formation Biologics Inc Polythérapie à base d'anticorps anti-egfr
KR101692044B1 (ko) * 2014-12-05 2017-01-04 사회복지법인 삼성생명공익재단 교모세포종에서 표피 성장인자 수용체 억제제의 치료 효과를 예측하는 방법
US20180117053A1 (en) * 2015-05-27 2018-05-03 Metastat, Inc. The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
RU2019134769A (ru) * 2017-03-31 2021-04-30 Дзе Кьюрейторз Оф Дзе Юниверсити Оф Миссури Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения
CN107496933B (zh) * 2017-08-21 2019-12-24 山东新华制药股份有限公司 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法
KR20230106506A (ko) * 2022-01-03 2023-07-13 한국생명공학연구원 Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
HU218140B (hu) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
AU2071695A (en) 1994-03-17 1995-10-03 Merck Patent Gmbh Anti-EGFR single-chain FVS and anti-EGFR antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999022008A1 (en) 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
PL357448A1 (en) * 2000-02-25 2004-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
BR0207283A (pt) 2001-02-19 2004-08-17 Merck Patent Gmbh Anticorpos anti-egfr modificados com imunogenicidade reduzida
ATE446317T1 (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
DE602004031772D1 (de) 2003-12-04 2011-04-21 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
DE602004022871D1 (de) 2003-12-22 2009-10-08 Glaxo Group Ltd Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
MXPA06010715A (es) 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
DK2439285T3 (da) 2004-03-31 2019-07-29 Massachusetts Gen Hospital Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US20060233814A1 (en) 2005-04-15 2006-10-19 Immunogen Inc. Elimination of heterogeneous or mixed cell population in tumors
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
CA2660463C (en) 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a
US20090258442A1 (en) 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
CN101711284A (zh) * 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
WO2008098145A1 (en) 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
DK2132229T3 (en) 2007-03-01 2016-06-20 Symphogen As Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS
US7892777B2 (en) 2007-07-17 2011-02-22 The Regents Of The University Of Michigan Methods for measuring whether a treatment affects RPTP-κ activity
WO2009030239A1 (en) 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
RU2503687C2 (ru) 2008-04-30 2014-01-10 Иммьюноджен, Инк. Сшивающие реагенты и их применение
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
RU2523419C2 (ru) 2008-07-15 2014-07-20 Дженетек, Инк. Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN105218673A (zh) 2008-10-10 2016-01-06 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
US20110287036A1 (en) 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
KR20120080611A (ko) * 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
CN103003424B (zh) 2010-05-18 2015-05-13 株式会社医学生物学研究所 结合转化生长因子α且对Ras基因突变的癌具有增殖抑制活性的抗体
CN103298489A (zh) * 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
EP2794010A4 (en) 2011-11-21 2015-10-21 Immunogen Inc METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE

Also Published As

Publication number Publication date
WO2013078271A1 (en) 2013-05-30
CN104066481A (zh) 2014-09-24
US20130156796A1 (en) 2013-06-20
US9233171B2 (en) 2016-01-12
PH12014501119A1 (en) 2014-08-04
CA2856411A1 (en) 2013-05-30
MX2014006087A (es) 2014-08-01
EP2794010A4 (en) 2015-10-21
SG11201402343SA (en) 2014-06-27
BR112014012155A2 (pt) 2017-05-30
JP2014533954A (ja) 2014-12-18
KR20140105765A (ko) 2014-09-02
EP2794010A1 (en) 2014-10-29
IL232666A0 (en) 2014-07-31
AU2012340686A1 (en) 2014-06-19
CL2014001282A1 (es) 2014-11-14
RU2014121820A (ru) 2015-12-27

Similar Documents

Publication Publication Date Title
HK1201772A1 (en) Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
IN2015KN00350A (cg-RX-API-DMAC7.html)
IN2014DN10889A (cg-RX-API-DMAC7.html)
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2012159085A3 (en) Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
WO2011063237A3 (en) Jagged-binding agents and uses thereof
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
HK1198135A1 (en) Prevention and treatment of pain using antibodies to lysophosphatidic acid
WO2013170263A3 (en) Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2012143382A9 (en) Gpr177 as target and marker in tumors
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.